In brief
In a significant change at the FDA, Dr. Tracy Beth Hoeg has been removed as the acting director of the agency’s drug program. This decision is part of a broader shake-up within the FDA following complaints from various groups and earlier resignations, including that of Commissioner Marty Makary. Hoeg, known for her controversial stances on vaccinations and drugs, had been leading critical inquiries on the safety of several medications. The agency has experienced a rapid turnover in leadership, contributing to concerns about its operational stability.
WASHINGTON (AP) — In a notable shake-up at the Food and Drug Administration (FDA), Dr. Tracy Beth Hoeg, who had been scrutinizing the safety of antidepressants and COVID-19 vaccines, has been removed from her position as the acting director of the agency’s drug program. This decision comes amidst ongoing leadership changes within the FDA, including the recent resignation of Commissioner Marty Makary.
Dr. Hoeg's replacement has been identified as Dr. Mike Davis, the agency’s deputy director. Following her dismissal, Hoeg expressed her feelings on social media, stating that she was “fired” from her position but holds no regrets about her time at the FDA.
The FDA has been facing a series of challenges, including internal disagreements and external pressures from political allies of past administration members related to the agency's direction. Hoeg had a quick rise through the agency, moving from special assistant to overseeing one of the FDA's largest centers, despite lacking prior government or leadership experience. Her abrupt departure adds to a growing list of leadership changes at the FDA which include other top officials stepping down due to criticism from various stakeholders in the healthcare sector.
As part of her tenure, Hoeg led investigations into the safety of several important medical treatments. She also worked on controversial topics such as vaccine safety, where she previously supported claims regarding vaccine-related adverse effects without solid evidence, contributing to a polarized environment at the agency.
Following the trends seen within the FDA, the appointment of new directors, including Karim Mikhail as acting director for the vaccines center, indicates an uncertain future for the agency as it navigates political and public health landscapes.
